Research Activity
Huntington’s Disease Clinical Trials: Updates on Dalzanemdor and Tominersen
Huntington’s disease, clinical trials, dalzanemdor, tominersen, cognitive impairment, RNA-based therapy, NMDA receptor modulator, Phase 2 and Phase 3 studies
Skye Bioscience Abandons Eye Disease Pipeline, Shifts Focus to Obesity Treatment After Phase 2a Trial Failure
Skye Bioscience, eye disease, Phase 2a trial, obesity treatment, stock price, biotech company
Boehringer Ingelheim and Zealand Unveil Promising Fibrosis Data from Mid-Stage MASH Trial
Boehringer Ingelheim, Zealand, fibrosis, MASH trial, mid-stage, Phase II data, liver scarring, treatment
AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success
AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere
AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment
AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology
Vir Biotechnology Reports Positive Update on Hepatitis Delta Combination and Monotherapy Treatments
Vir Biotechnology, Hepatitis Delta, Combination Therapy, Monotherapy, Clinical Trial, EASL Congress
ConcertAI Partners with NVIDIA, Unveils Advanced AI Tools for Oncology Research and Treatment
ConcertAI, NVIDIA, AI tools, oncology research, clinical simulations, CARA AI platform, multi-modal oncology data, clinical trials, patient outcomes
Bulevirtide: A Novel Treatment for Chronic Hepatitis Delta Virus Infection
Bulevirtide, Hepatitis Delta Virus (HDV), Chronic Infection, Antiviral Therapy, Clinical Trials, Efficacy, Safety
Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy
Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials
Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results
Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders